Type-2 diabetes mellitus therapeutic - HSRx Biopharmaceutical

Drug Profile

Type-2 diabetes mellitus therapeutic - HSRx Biopharmaceutical

Latest Information Update: 03 Dec 2016

Price : $50

At a glance

  • Originator HerbalScience Group
  • Developer HSRx Biopharmaceutical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 01 Dec 2016 Phase-I clinical trials in Type-2 diabetes mellitus (PO)
  • 05 Aug 2015 HSRx Biopharmaceutical in-licenses 8 proprietary pharmaceutical products from HerbalScience Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top